DeepMed Research

Urokinase

Generic Name: Urokinase

Brand Names: Kinlytic

Drug Type: Biotech

CAS Number: 9039-53-6

Unique Ingredient Identifier: 83G67E21XI

Background: Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond.

Urokinase was granted FDA approval on 16 January 1978.

Indication: In Canada, urokinase is indicated for lysis of acute massive pulmonary emboli, acute thrombi obstructing coronary arteries, occlusive thromboemboli in peripheral arteries and grafts, and restoration of patency to intravenous catheters.

Associated Conditions: Obstruction; Catheter, Infusion Catheter (Vascular), Pulmonary Embolism, Pulmonary Embolism Acute Massive, Thromboembolism of the Coronary Artery, Thromboembolism of the Graft, Thromboembolism of the Peripheral Artery

Clinical Trials

Safety and Efficacy Study of Urokinase for the Treatment of Diabetic Foot Syndrome and Critical Limb Ischemia

Phase 3

Terminated

Conditions: Critical Limb Ischemia
Diabetic Foot

Interventions: Drug: urokinase

First Posted Date: 2012-07-11

Last Posted Date: 2014-04-07

Lead Sponsor: GWT-TUD GmbH

Target Recruit Count: 34

Registration Number: NCT01638585

Locations: 🇩🇪
Städtisches Krankenhaus DD-Neustadt, Dresden, Germany
🇩🇪
Klinikum Westfalen/Klinikum am Park, Lünen, Germany
🇩🇪
Vivantes Klinikum im Friedrichshain, Berlin, Germany

and more 15 locations

Local Thrombolytics Before Thrombectomy in STEMI

Phase 4

Conditions: Coronary Artery Disease

Interventions: Drug: Saline
Drug: Urokinase

First Posted Date: 2012-04-02

Last Posted Date: 2020-04-08

Lead Sponsor: University of Roma La Sapienza

Target Recruit Count: 100

Registration Number: NCT01568931

Intrapleural Urokinase for Retained Hemothorax

Phase 3

Conditions: Retained Hemothorax

Interventions: Drug: urokinase
Drug: placebo

First Posted Date: 2010-05-31

Last Posted Date: 2010-05-31

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 32

Registration Number: NCT01134237

Locations: 🇨🇳
Chin-Chih Chang, Taipei, Taiwan

Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)

Phase 4

Completed

Conditions: Pulmonary Embolism
Pulmonary Thromboembolism

Interventions: Drug: Recombinant Streptokinase
Drug: Urokinase

First Posted Date: 2009-08-31

Last Posted Date: 2009-09-01

Lead Sponsor: Beijing Chao Yang Hospital

Target Recruit Count: 83

Registration Number: NCT00968929

Locations: 🇨🇳
The General Hospital of Shenyang Military Command, Shenyang, Liaoning, China
🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳
Guangdong Institute of Respiratory Disease, Guangzhou Medical University,, Guangzhou, Guangdong, China

and more 5 locations

Urokinase Therapy in Patients With Diabetic Foot Syndrome

Phase 3

Terminated

Conditions: Diabetic Foot
Ischemia
Arterial Occlusive Disease

Interventions: Procedure: standard therapy
Drug: Urokinase

First Posted Date: 2009-01-15

Last Posted Date: 2015-03-13

Lead Sponsor: medac GmbH

Target Recruit Count: 5

Registration Number: NCT00823225

Locations: 🇩🇪
Franziskus Krankenhaus, Berlin, Germany
🇩🇪
Klinikum Dortmund Nord GmbH, Dortmund, Germany
🇩🇪
Klinikum Karlsbad Langensteinbach, Karlsbad, Germany

and more 3 locations

12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China

Phase 4

Completed

Conditions: Pulmonary Embolism
Thromboembolism

Interventions: Drug: Urokinase

First Posted Date: 2008-12-01

Last Posted Date: 2008-12-01

Lead Sponsor: Beijing Chao Yang Hospital

Target Recruit Count: 129

Registration Number: NCT00799968

Locations: 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳
The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳
Tangshan Worker's Hospital, Hebei Medical University, Tangshan, Hebei, China

and more 28 locations

Urokinase Versus Video-assisted Thoracoscopic to Treat Complicated Parapneumonic Empyema in Childhood

Phase 3

Completed

Conditions: Empyema
Pneumonia

Interventions: Drug: Urokinase
Procedure: Video-Assisted Thoracoscopic

First Posted Date: 2008-11-26

Last Posted Date: 2010-10-28

Lead Sponsor: Spanish Society of Pediatric Surgery

Target Recruit Count: 200

Registration Number: NCT00798278

Locations: 🇪🇸
Hospital Infantil La Paz, Madrid, Spain
🇪🇸
Hospital de Donostia, San Sebastián, Donostia, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain

and more 3 locations

Urokinase Therapy in Diabetic Foot Syndrome

Phase 2

Completed

Conditions: Ischemia
Diabetic Foot
Arterial Occlusive Disease

Interventions: Drug: Urokinase

First Posted Date: 2007-10-01

Last Posted Date: 2010-03-25

Lead Sponsor: medac GmbH

Target Recruit Count: 77

Registration Number: NCT00537498

Locations: 🇩🇪
Universitätsklinikum Carl Gustav Carus UniversitätsGefäßcentrum, Dresden, Germany

Dornase Alfa and Urokinase for Kids With Pleural Empyema

Phase 2

Conditions: Pleural Empyema

Interventions: Drug: Urokinase and Dornase alfa
Drug: Urokinase

First Posted Date: 2007-07-17

Last Posted Date: 2008-05-12

Lead Sponsor: Azienda Ospedaliera di Padova

Target Recruit Count: 94

Registration Number: NCT00502632

Locations: 🇮🇹
Azienda Ospedaliera di Padova, Padova, Italy
🇮🇹
Ospedali Riuniti di Bergamo, Bergamo, Italy
🇮🇹
Ospedale Bambino Gesu', Roma, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy